200
Views
15
CrossRef citations to date
0
Altmetric
Drug Evaluation

Valproate semisodium ER for migraine and cluster headache prophylaxis

, DMD (Headache Fellow) & , MD (Assistant Professor of Neurology)
Pages 495-504 | Published online: 19 Mar 2010

Bibliography

  • Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004;24:1-160
  • Lipton RB, Stewart WF, Diamond S, Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646-57
  • Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53(3):537-42
  • Giffin NJ, Ruggiero L, Lipton RB, Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60(6):935-40
  • Dodick DW, Silberstein SD. Migraine prevention. Practical Neurol 2007;7(6):383-93
  • Gold L, Black T, Arnold G, Cortical spreading depression-associated hyperemia in rats: involvement of serotonin. Brain Res 1998;783:1983
  • Bradley DP, Smith MI, Netsiri C, Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and Tonabersat. Exp Neurol 2001;172:342-53
  • Uddman R, Edvinsson L, Ekman R, Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985;62:131-6
  • Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
  • Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol 2004;3:279-83
  • Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002;58:354-61
  • Dodick DW, Rozen TD, Goadsby PJ, Cluster headache. Cephalgia 2000;20:787-803
  • Ekbom K, Monstad I, Prusinski A, Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993;88:63-9
  • Kudrow L. Response of cluster headache attacks to oxygen inhalation. Intranasal medications for the treatment of migraine and cluster headache. Headache 1981;21(1):1-4
  • Markley HG. Topical agents in the treatment of cluster headache. Curr Pain Headache Rep 2003;7(2):139-43
  • Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache 1983;23:266-77
  • Ekbom K. Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache 1981;21:132-9
  • Jammes JL. The treatment of cluster headaches with prednisone. Dis Nerv Syst 1975;36:375-6
  • Silberstein S, Tfelt-Hansen P, Dodick DW, Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28(5):484-95
  • Diener H-C, Dw Dodick, Pj Goadsby, Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009;29(10):1021-7
  • Silberstein SD for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
  • Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9
  • Rozen TD, Oshinsky ML, Gebeline CA, Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41
  • Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-70
  • Lipton RB, Gobel H, Einhaupl KM, Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240-44
  • Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512
  • Silberstein SD. Migraine: preventative treatment. Curr Med Res Opin 2001;17(Suppl 1):s87-93
  • Verrotti A, Salladini C, diMarco G, Extended-release formulations in epilepsy. J Child Neurol 2007;22(4):419-26
  • Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714
  • Bazil CW, Pedley TA. Clinical pharmacology of antiepileptic drugs. Clinical neuropharmacology. Volume 26, Lippincott Williams and Wilkins, Inc.; 2003. p. 38-52
  • Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-90
  • Ayata C, Jin H, Kudo C, Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59(4):652-61
  • Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004;25(8):345-52
  • Freitag FG, Diamond S, Diamond M, Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41:271-8
  • Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 2004;5:746-51
  • Pellock JM, andWillmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991;41:961-4
  • Zarate CA Jr, Tohen M, Narendran R, The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999;60(4):232-6
  • Silberstein SD. Divalproex sodium in headache-literature review and clinical guidelines. Headache 1996;36:547-55
  • Pascual J, Leira R, Láinez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003;23(10):961-2
  • Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008;118(5):281-90
  • Driefuss FE, Santilli N, Langer DH, Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-85
  • Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol 2008;24(10):562-70
  • Gomceli YB, Kutlu G, Cavdar L, Valproate-induced hyperammonemic encephalopathy with normal liver function. Epilepsy Behav 2007;10(4):583-7
  • Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009;47(2):101-11
  • Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol 2009;32(6):350-2
  • Kalinin W. Suicidality and antiepileptic drugs: is there a link? Drug Saf 2007:30(2):123-42
  • Hesdorffer D, Kanner A. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009:50(5):978-86
  • James L, Barnes TR, Lelliott P, Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol 2007;21:815
  • Harden CL, Pennell PB, Koppel BS, American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50(5):1247-55
  • Meador K, Reynolds MW, Crean S, Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008:81(1):1-13
  • Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010;33(1):73-9
  • Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61(6 Suppl 2):S35-42
  • Díaz RA, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist 2008;14(6 Suppl 1):S55-65
  • Vinar O, Dvorák A, Vinarová E, Does sodium valproate increase clinical effects of diazepam? Double blind study. Act Nerv Super (Praha) 1989;31(2):106-7
  • Yu HY, Shen YZ, Sugiyama Y, Hanano M. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. Drug Metab Dispos 1990;18(1):121-6
  • Freitag FG, Collins SD, Carlson HA, A randomized trial of divalproex sodium extended – release tablets in migraine prophylaxis. Neurology 2002;58:1652-9
  • Hering, R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4
  • Klapper JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-8
  • Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994;44:647-51
  • Mathew NT, Saper JR, Silberstein SD, Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
  • Apostol G, Lewis DW, Laforet GA, Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 2009;49:45-53
  • Apostol G, Cady RK, Laforet GA, Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48(7):1012-25
  • Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989;9:195-8
  • Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002;102:92-4
  • El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: methodological issues. Cephalalgia 2002:22:205-8
  • Wheeler SD. Significance of migrainous features in cluster headache: divalproex responsiveness. Headache 1998;38(7):547-51
  • Magnoux E., Zlotnik, G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache 2004;44(3):249-55
  • Peiris JB, Perera GL, Devendra SV, Lionel ND. Sodium valproate in trigeminal neuralgia. Med J Aust 1990;2(5):278
  • Waberzinek G, Marková J, Mastík J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007;28(1):59-64
  • Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004;44:65-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.